


available at www.sciencedirect.com







Corrigendum

Corrigendum to "Management of toxicity in patients receiving therapy with bevacizumab" [EJC Suppl. 6(6) (2008) 29–39]

David Miles*

Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK

The author regrets that there is an error in Table 2 of the article mentioned above.

Efficacy outcomes from the E2100 study are incorrectly cited as: median PFS (11.4 *versus* 5.8 months, p < 0.0001) response rate (48% *versus* 23.4%, p < 0.0001) and 1-year sur-

vival (81.4% versus 74.0%, p = 0.017). The correct data are as follows: median PFS (11.8 versus 5.9 months, p < 0.001) response rate (49.2% versus 25.2%, p < 0.001) and 1-year survival (81.2% versus 73.4%, p = 0.01).

DOI of original article: 10.1016/S1359-6349(08)70290-8

^{*} Address for correspondence: Department of Oncology, University of Leeds, Leeds, UK. Tel.: +44 1923 844291; fax: +44 1923 844840. E-mail address: david.miles@doctors.org